Physiological MonitoringNCT00664924
Comparative in Patient, Non-intervention Study of the Remote Physiological Monitoring System (RPM™) vs Standard Physiological Monitoring Devices
An observational study of Physiological Monitoring and Critically Ill, run by Ottawa Hospital Research Institute at 1 site in Canada.
Trial summary
The Remote Physiological Monitoring System (RPM™) is a wireless technology for physiological monitoring. The RPM™ is designed to capture, transmit and remotely monitor the vital signs of a patient or group of patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Physiological Monitoring, Critically Ill
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- Oct 2007to Dec 2008
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cohort 1 (Exercise): patients who are scheduled to undergo a minimum of 20 minutes of exercise testing. Cohort 2 (ICU): patients admitted to the Intensive Care Unit (ICU) Cohort 3 (Post-op): patients in Post-Operative care Cohort 4 (ER): patients admitted to the Emergency Room (e.g., high risk medical admissions) These cohorts are considered representative of a broad spectrum of the general patient population. Patients participating in the study will be assigned to one of these 4 cohorts, with a minimum of 10 patients assigned to Cohort 1 (Exercise) and a minimum of 5 patients in each of the other cohorts.
Who may be able to join
- The informed consent document must be read, signed, and dated by the patient (or legally authorized representative), the individual obtaining the consent, and a witness if appropriate, before conducting any study related procedures or examinations.
- Patients will be ≥18 years of age or older, of any race and either sex. Women who are pregnant may participate in the study.
- The RPM™ must not interfere with patient care.
- Investigator or Study Staff must be able to clearly access the sites for attaching sensors.
- Specific Inclusion Criteria for Cohort 1 (Exercise):
- Patients who are referred for Stage-I pre-operative exercise testing to assess fitness for surgery.
Show all 14Show fewer
- Patients who have a history of a chronic respiratory or cardiac condition resulting in symptoms with exertion.
- Specific Inclusion Criteria for Cohort 2 (ICU):
- � Patients admitted to the ICU on life support whose hospital stay is expected to be more than 72 hours.
- Specific Inclusion Criteria for Cohort 3 (Post-op):
- Patients undergoing surgery and post-operative recovery are expected to be more than 72 hours.
- A broad variety of patients with a history of coronary heart disease, congestive heart failure or chronic lung disease, and considered at high risk of cardiopulmonary complications; or patients who have undergone major thoracic surgery with a high risk of cardiopulmonary complications.
- Specific Inclusion Criteria for Cohort 4 (ER):
- � Patients who are admitted to a general medical ward from the ER whose hospital stay is expected to be more than 72 hours.
Who cannot join
- Patients with a history of any medical condition which would preclude completion of the study, e.g., patients whose skin disorders or excessive weight interfere with the proper functioning of standard monitoring.
- Patients with significant unstable disease that could compromise the study assessments and/or participation in the study.
- The PI or the Medical Monitor may declare a patient ineligible for a valid medical reason or where the patient's condition or patient's actions may be inappropriate for inclusion in a study of this design.
- Specific Exclusion Criteria for Cohort 1 (Exercise):
- Patients who would not tolerate a standard exercise test such as patients who have severe peripheral vascular disease, disabling arthritis or neurological condition;
- Patients who have had a significant change in symptoms since referral (e.g., unstable angina, recent myocardial infarction).
Show all 12Show fewer
- Specific Exclusion Criteria for Cohort 2 (ICU), 3, \& 4:
- Patients who are severely agitated;
- Patients where increased monitoring may interfere with the provision of clinical care;
- Patients where the family or the attending team are not committed to providing all necessary aggressive supportive care;
- Patients who are considered brain dead;
- Patients where standard sensors are not capturing such as unstable patients with severe peripheral vascular disease where saturation probes do not function properly.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative In-patient, Non-intervention Study of the Remote Physiological Monitoring System (RPM™), a Non-invasive, Remote, Ambulatory Vital Signs Monitoring Device, Versus Standard Physiological Monitoring Devices by Simultaneous Monitoring of Heart Rate, ECG, SpO2, Blood Pressure, Body Temperature, and Respiration Rate in a 24 hr Monitoring Period (BRYTECH #BRY-C-01-06-RPM)
The Remote Physiological Monitoring System (RPM™) is a wireless technology for physiological monitoring. The RPM™ is designed to capture, transmit and remotely monitor the vital signs of a patient or group of patients. The RPM™ allows the patient to carry an unobtrusive unit and sensor array, which is able to store and/or forward its data via existing communication networks. This data is archivable and can be made available to a monitoring station or stations. This approach obviates the need to provide new and expensive infrastructure to support the system since it is designed to 'piggy-back' on the existing network.
A major clinical advantage of the RPM™ and the principal reason why it may offer a benefit to patients, is that it provides continuous remote monitoring of vital signs, in contrast to the current situation for ward patients, where there is intermittent vital signs monitoring. This is a major advantage for patients and hospital staff, since there is increasing evidence that demonstrate early recognition and treatment of clinical events, e.g., shock, can save lives; the concurrent cost and labour saving is a further obvious benefit.
Read more
The RPM™ uses wireless technology to overcome the portability problems associated with conventional patient monitoring systems. The RPM™ consists of the following system components:
- Physiological Monitoring Unit (PMU)
- Data Aggregation Server (DAS)
- Clinical Monitoring Position (CMP) To validate the RPM™ device for regulatory approval, BRYTECH will evaluate the RPM™ in a clinical setting, thereby ensuring that the system is trustworthy and acceptable to health professionals as a monitoring system in patients. The study proposes to evaluate the accuracy and reliability of the RPM™ compared to monitors commonly used in the medical practice under the standard conditions of medical practice The study also proposes to evaluate notification and alarm systems, the communications interface and non-interference with existing systems, devices, networks and procedures as well as the incremental nursing workload associated with the integration of the RPM™ in a clinical environment. The RPM™ and reference physiological monitoring devices will be compared for physiological monitoring capabilities in 40 patients.
Read the detailed description
BRYTECH STUDY SUMMARY
The Remote Physiological Monitoring System (RPM™) is a wireless technology for physiological monitoring. The RPM™ is designed to capture, transmit and remotely monitor the vital signs of a patient or group of patients. The RPM™ allows the patient to carry an unobtrusive unit and sensor array, which is able to store and/or forward its data via existing communication networks. This data is archivable and can be made available to a monitoring station or stations. This approach obviates the need to provide new and expensive infrastructure to support the system since it is designed to 'piggy-back' on the existing network.
A major clinical advantage of the RPM™ and the principal reason why it may offer a benefit to patients, is that it provides continuous remote monitoring of vital signs, in contrast to the current situation for ward patients, where there is intermittent vital signs monitoring. This is a major advantage for patients and hospital staff, since there is increasing evidence that demonstrate early recognition and treatment of clinical events, e.g., shock, can save lives; the concurrent cost and labour saving is a further obvious benefit.
The RPM™ uses wireless technology to overcome the portability problems associated with conventional patient monitoring systems. The RPM™ uses off the shelf computer technology such as standard displays, as well as secure, wireless, 802.11 networking protocols and consists of the following system components:
- Physiological Monitoring Unit (PMU)
- Data Aggregation Server (DAS)
- Clinical Monitoring Position (CMP)
To validate the RPM™ device for regulatory approval, BRYTECH will evaluate the RPM™ in a clinical setting, thereby ensuring that the system is trustworthy and acceptable to health professionals as a monitoring system in patients. The study proposes to evaluate the accuracy and reliability of the RPM™ compared to monitors commonly used in the medical practice under the standard conditions of medical practice; this study will therefore be a non-intervention study. The study also proposes to evaluate notification and alarm systems, the communications interface and non-interference with existing systems, devices, networks and procedures as well as the incremental nursing workload associated with the integration of the RPM™ in a clinical environment. The RPM™ and reference physiological monitoring devices will be compared for physiological monitoring capabilities in 40 patients from the following four (4) cohorts:
- Cohort 1 (Exercise): patients who are scheduled to undergo a minimum of 20 minutes of exercise testing.
- Cohort 2 (ICU): patients admitted to the Intensive Care Unit (ICU)
- Cohort 3 (Post-op): patients in Post-Operative care
- Cohort 4 (ER): patients admitted to the Emergency Room (e.g., high risk medical admissions) These cohorts are considered representative of a broad spectrum of the general patient population. Patients participating in the study will be assigned to one of these 4 cohorts, with a minimum of 10 patients assigned to Cohort 1 (Exercise) and a minimum of 5 patients in each of the other cohorts.
For the study, the RPM™ and reference monitoring devices will be time-stamped such that zero time will be readily evaluable and patients will be fitted with all necessary sensors for collection of vital signs, namely heart rate (HR), electrocardiogram (ECG), blood oxygen saturation levels (SpO2), non-invasive blood pressure (NIBP), body temperature (BT) and respiration rate (RR).
For Cohort 1 (Exercise) patients, comparative monitoring of vital signs will be done during exercise testing for a minimum of 20 minutes with additional monitoring performed pre- and post-exercise. There will be a minimum of 10 patients in this cohort. For patients in Cohorts 2, 3 and 4, comparative monitoring of vital signs will be performed during the period (24 - 72 hours) required to collect 12 Vital Sign Assessment Cycles (VSAC - defined in Section 5.2.2) per subject, with a minimum of 5 patients in each cohort and a total of 30 patients. The four cohorts of patients have been chosen to allow comparison of vital signs from the RPM™ and standard nursing measurement techniques over a broad range of physiologic data (e.g. rest and exercise) and patient populations (e.g. stable and critically ill).The primary objective for the study is to determine substantial equivalence of the RPM™ and the reference devices or standard practice measurements by comparing the agreement (accuracy) between paired output results for individual vital signs and the reliability of data collection over a 24 hour monitoring period. Timepoint matched paired data for all available timepoints will be collected from the RPM™ and the reference devices, excluding ambulatory data, for heart rate, ECG, SpO2, blood pressure, body temperature and respiration rate. Accuracy will be determined by assessing whether the paired values show significant agreement. Reliability will be determined by a comparison of cumulative totals for lost data points and error rates.
The study will be conducted according to Good Clinical Practice (GCP) guidelines with all patients required to sign an Informed Consent Form (ICF). This is a non-intervention study and patients tested will be subjected to use of the RPM™ as the only experimental procedure during the trial. Importantly, patients will not be exposed to any significant risks as a result of participating in this study.
- Conditions
- Physiological Monitoring, Critically Ill
- Keywords
- ICU
- Medical subject headings
- Critical Illness
What is being measured
The primary outcome is the main question the study is designed to answer.
measurement and accurate transmission of data
Measured: June 2008
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2008 (estimated)
- Study startOct 2007
- Primary completionDec 2008
- Study completionDec 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Physiological MonitoringStudies of the same condition, open and under way.
- More trials run by Ottawa Hospital Research InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ottawa Hospital Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- BryTech, Inc.
- Responsible party
- Sponsor
- Investigators
- Andrew Seely, MD, Principal investigator, Ottawa Hospital Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00664924
- Sponsor's protocol ID
- BRY-C-01-06-RPM
- Other IDs
- OHREB #2006712-01H
- Status last verified
- Jan 2017
- First submitted
- 21 Apr 2008
- Last updated
- 23 Jan 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative In-patient, Non-intervention Study of the Remote Physiological Monitoring System (RPM™), a Non-invasive, Remote, Ambulatory Vital Signs Monitoring Device, Versus Standard Physiological Monitoring Devices by Simultaneous Monitoring of Heart Rate, ECG, SpO2, Blood Pressure, Body Temperature, and Respiration Rate in a 24 hr Monitoring Period (BRYTECH #BRY-C-01-06-RPM)
- ClinicalTrials.gov ID
- NCT00664924
- Acronym / sponsor ID
- BRY-C-01-06-RPM
- Conditions
- Physiological Monitoring, Critically Ill
- Keywords
- ICU
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Ottawa Hospital Research InstituteUniversity, hospital or other
- Collaborators
- BryTech, Inc.
- Study start
- Oct 2007
- Primary completion
- Dec 2008 (actual)
- Study completion
- Dec 2008 (actual)
- First posted
- 23 Apr 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Remote Physiological Monitoring System (RPM™) is a wireless technology for physiological monitoring. The RPM™ is designed to capture, transmit and remotely monitor the vital signs of a patient or group of patients. The RPM™ allows the patient to carry an unobtrusive unit and sensor array, which is able to store and/or forward its data via existing communication networks. This data is archivable and can be made available to a monitoring station or stations. This approach obviates the need to provide new and expensive infrastructure to support the system since it is designed to 'piggy-back' on the existing network.
A major clinical advantage of the RPM™ and the principal reason why it may offer a benefit to patients, is that it provides continuous remote monitoring of vital signs, in contrast to the current situation for ward patients, where there is intermittent vital signs monitoring. This is a major advantage for patients and hospital staff, since there is increasing evidence that demonstrate early recognition and treatment of clinical events, e.g., shock, can save lives; the concurrent cost and labour saving is a further obvious benefit.
The RPM™ uses wireless technology to overcome the portability problems associated with conventional patient monitoring systems. The RPM™ consists of the following system components:
- Physiological Monitoring Unit (PMU)
- Data Aggregation Server (DAS)
- Clinical Monitoring Position (CMP) To validate the RPM™ device for regulatory approval, BRYTECH will evaluate the RPM™ in a clinical setting, thereby ensuring that the system is trustworthy and acceptable to health professionals as a monitoring system in patients. The study proposes to evaluate the accuracy and reliability of the RPM™ compared to monitors commonly used in the medical practice under the standard conditions of medical practice The study also proposes to evaluate notification and alarm systems, the communications interface and non-interference with existing systems, devices, networks and procedures as well as the incremental nursing workload associated with the integration of the RPM™ in a clinical environment. The RPM™ and reference physiological monitoring devices will be compared for physiological monitoring capabilities in 40 patients.
Detailed description
BRYTECH STUDY SUMMARY
The Remote Physiological Monitoring System (RPM™) is a wireless technology for physiological monitoring. The RPM™ is designed to capture, transmit and remotely monitor the vital signs of a patient or group of patients. The RPM™ allows the patient to carry an unobtrusive unit and sensor array, which is able to store and/or forward its data via existing communication networks. This data is archivable and can be made available to a monitoring station or stations. This approach obviates the need to provide new and expensive infrastructure to support the system since it is designed to 'piggy-back' on the existing network.
A major clinical advantage of the RPM™ and the principal reason why it may offer a benefit to patients, is that it provides continuous remote monitoring of vital signs, in contrast to the current situation for ward patients, where there is intermittent vital signs monitoring. This is a major advantage for patients and hospital staff, since there is increasing evidence that demonstrate early recognition and treatment of clinical events, e.g., shock, can save lives; the concurrent cost and labour saving is a further obvious benefit.
The RPM™ uses wireless technology to overcome the portability problems associated with conventional patient monitoring systems. The RPM™ uses off the shelf computer technology such as standard displays, as well as secure, wireless, 802.11 networking protocols and consists of the following system components:
- Physiological Monitoring Unit (PMU)
- Data Aggregation Server (DAS)
- Clinical Monitoring Position (CMP)
To validate the RPM™ device for regulatory approval, BRYTECH will evaluate the RPM™ in a clinical setting, thereby ensuring that the system is trustworthy and acceptable to health professionals as a monitoring system in patients. The study proposes to evaluate the accuracy and reliability of the RPM™ compared to monitors commonly used in the medical practice under the standard conditions of medical practice; this study will therefore be a non-intervention study. The study also proposes to evaluate notification and alarm systems, the communications interface and non-interference with existing systems, devices, networks and procedures as well as the incremental nursing workload associated with the integration of the RPM™ in a clinical environment. The RPM™ and reference physiological monitoring devices will be compared for physiological monitoring capabilities in 40 patients from the following four (4) cohorts:
- Cohort 1 (Exercise): patients who are scheduled to undergo a minimum of 20 minutes of exercise testing.
- Cohort 2 (ICU): patients admitted to the Intensive Care Unit (ICU)
- Cohort 3 (Post-op): patients in Post-Operative care
- Cohort 4 (ER): patients admitted to the Emergency Room (e.g., high risk medical admissions) These cohorts are considered representative of a broad spectrum of the general patient population. Patients participating in the study will be assigned to one of these 4 cohorts, with a minimum of 10 patients assigned to Cohort 1 (Exercise) and a minimum of 5 patients in each of the other cohorts.
For the study, the RPM™ and reference monitoring devices will be time-stamped such that zero time will be readily evaluable and patients will be fitted with all necessary sensors for collection of vital signs, namely heart rate (HR), electrocardiogram (ECG), blood oxygen saturation levels (SpO2), non-invasive blood pressure (NIBP), body temperature (BT) and respiration rate (RR).
For Cohort 1 (Exercise) patients, comparative monitoring of vital signs will be done during exercise testing for a minimum of 20 minutes with additional monitoring performed pre- and post-exercise. There will be a minimum of 10 patients in this cohort. For patients in Cohorts 2, 3 and 4, comparative monitoring of vital signs will be performed during the period (24 - 72 hours) required to collect 12 Vital Sign Assessment Cycles (VSAC - defined in Section 5.2.2) per subject, with a minimum of 5 patients in each cohort and a total of 30 patients. The four cohorts of patients have been chosen to allow comparison of vital signs from the RPM™ and standard nursing measurement techniques over a broad range of physiologic data (e.g. rest and exercise) and patient populations (e.g. stable and critically ill).The primary objective for the study is to determine substantial equivalence of the RPM™ and the reference devices or standard practice measurements by comparing the agreement (accuracy) between paired output results for individual vital signs and the reliability of data collection over a 24 hour monitoring period. Timepoint matched paired data for all available timepoints will be collected from the RPM™ and the reference devices, excluding ambulatory data, for heart rate, ECG, SpO2, blood pressure, body temperature and respiration rate. Accuracy will be determined by assessing whether the paired values show significant agreement. Reliability will be determined by a comparison of cumulative totals for lost data points and error rates.
The study will be conducted according to Good Clinical Practice (GCP) guidelines with all patients required to sign an Informed Consent Form (ICF). This is a non-intervention study and patients tested will be subjected to use of the RPM™ as the only experimental procedure during the trial. Importantly, patients will not be exposed to any significant risks as a result of participating in this study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cohort 1 (Exercise): patients who are scheduled to undergo a minimum of 20 minutes of exercise testing. Cohort 2 (ICU): patients admitted to the Intensive Care Unit (ICU) Cohort 3 (Post-op): patients in Post-Operative care Cohort 4 (ER): patients admitted to the Emergency Room (e.g., high risk medical admissions) These cohorts are considered representative of a broad spectrum of the general patient population. Patients participating in the study will be assigned to one of these 4 cohorts, with a minimum of 10 patients assigned to Cohort 1 (Exercise) and a minimum of 5 patients in each of the other cohorts.
Key inclusion criteria (14 listed)
- The informed consent document must be read, signed, and dated by the patient (or legally authorized representative), the individual obtaining the consent, and a witness if appropriate, before conducting any study related procedures or examinations.
- Patients will be ≥18 years of age or older, of any race and either sex. Women who are pregnant may participate in the study.
- The RPM™ must not interfere with patient care.
- Investigator or Study Staff must be able to clearly access the sites for attaching sensors.
- Patients who are referred for Stage-I pre-operative exercise testing to assess fitness for surgery.
Key exclusion criteria (12 listed)
- Patients with a history of any medical condition which would preclude completion of the study, e.g., patients whose skin disorders or excessive weight interfere with the proper functioning of standard monitoring.
- Patients with significant unstable disease that could compromise the study assessments and/or participation in the study.
- The PI or the Medical Monitor may declare a patient ineligible for a valid medical reason or where the patient's condition or patient's actions may be inappropriate for inclusion in a study of this design.
- Patients who would not tolerate a standard exercise test such as patients who have severe peripheral vascular disease, disabling arthritis or neurological condition;
- Patients who have had a significant change in symptoms since referral (e.g., unstable angina, recent myocardial infarction).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
measurement and accurate transmission of data
Time frame: June 2008
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2017.
Related trials for Physiological Monitoring
Not yet recruitingObservational study
Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery
Postoperative Cognitive Complications, Delirium
Not yet recruitingObservational study
Prospective Observational Multimodal Neuromonitoring in Adult NSICU Patients
Subarachnoid Hemorrhage, Aneurysmal, Brain Injuries, Traumatic
Enrolling by invitationObservational study
Intelligent Physiological Monitoring to Predict Preterm Brain Injury
Cerebral Palsy (CP), Intraventricular Hemorrhage Neonatal
Active, not recruitingObservational study
Wearable Suicidal Early Warning System for Adolescents
Suicide, Adolescent Behavior
Not yet recruitingObservational study
Evaluation of the UltraTrac System as a Non-Invasive Monitor of Hemodynamic Parameters
Hemodynamic Monitoring
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrew Seely, MD principal investigator
Ottawa Hospital Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Physiological Monitoring and Critically Ill, run by Ottawa Hospital Research Institute at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jan 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
measurement and accurate transmission of data (time frame: June 2008). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2017.